The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2025 | Integrating emerging small cell lung cancer therapies into NHS practice
Anna Minchom, MD, BCh, MB, MRCP, The Royal Marsden Hospital, London, UK, discusses the integration of emerging small cell lung cancer therapies, such as T-cell engagers, into NHS practice. While the NHS has the expertise and infrastructure to adopt these treatments, challenges remain due to resource constraints. She emphasizes the need for comprehensive training, protocol development for managing cytokine release syndrome, and continuous data collection to refine treatment approaches. This interview took place at the BTOG 2025 congress in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
